Ms. Jennifer CHE, J.D., Vice President and Principal of Eagle IP Limited, shared about the unique IP challenges biomedical innovations in the GBA and China face. She demonstrated how a strategic approach to IP is crucial – especially at the earliest stages – to avoiding messy issues down the road. She finally touched upon what unique role Hong Kong can play to help protect and cultivate future important biomedical inventions arising out of the GBA and China.
我們過去活動
Recommended Insights
Markush claims in China - what can be arbitrarily deleted during invalidation?
2018年12月4日Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that […]
閱讀更多 >
China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines
2021年10月19日The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
閱讀更多 >
China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux
2021年5月24日The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
閱讀更多 >
CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals
2021年12月6日In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]
閱讀更多 >